Lir, also known as Victoza, was purchased from Novo Nordisk A/S (Copenhagen, Denmark). GSK2606414, a PERK inhibitor, was purchased from the Merck KGaA Group (Darmstadt, Germany). Dimethyl sulfoxide (DMSO) was purchased from Sigma-Aldrich (St. Louis, MO, USA). The Cell Counting Kit-8 (CCK-8) kit was purchased from Beijing Solarbio Science & Technology Co., Ltd. (Beijing, China). The human CNPY2 enzyme-linked immunosorbent assay (ELISA) kit was purchased from Proteintech Group (Chicago, IL, USA). The hypoxia-inducible factor 1α (HIF1α) and vascular endothelial growth factor (VEGF) ELISA kits were purchased from Abcam (Cambridge, UK).
To increase the physiology-related possibilities observed in these studies, human umbilical vein endothelial cells (HUVECs) were used in the experiment. In addition, the concentration of Lir used was 100 nM, which is within the therapeutic range of 1.8 mg/day human injection of Victoza, a widely used clinical brand of Lir (Krasner et al., 2014 (link)).
To increase the physiology-related possibilities observed in these studies, human umbilical vein endothelial cells (HUVECs) were used in the experiment. In addition, the concentration of Lir used was 100 nM, which is within the therapeutic range of 1.8 mg/day human injection of Victoza, a widely used clinical brand of Lir (Krasner et al., 2014 (link)).
Free full text: Click here
